MAPT and Alzheimer disease: NfL lacks the pathophysiological specificity of the classical CSF AD biomarkers and, therefore, it is advisable to use it in addition to Aβ42, t-tau, and p-tau in the diagnostic management of AD patients as a general marker of neurodegeneration [44].